DAWN - Rasio rega marang prakiraan pendapatan Day One Biopharmaceuticals

The future P/S metric correlates with the use of automated drug synthesis and development algorithms, with the parameter reaching 14.00. Day One is currently scaling sales of its first approved drug while expanding its hospital network and molecule portfolio. A noble mission to save children and generous stock options help the company attract leading scientists and clinicians.

Day One Biopharmaceuticals, Inc. - Prakiraan rega marang pendapatan DAWN (periode 01.08.2024 - 09.05.2026)

Rincian metrik komprehensif lan analitis Day One Biopharmaceuticals Inc (DAWN)

- rega pasar lan target rega analis:

Bagan rega Day One Biopharmaceuticals|DAWN - Bagan rega target

- statistik kapitalisasi pasar:

Nilai pasar Day One Biopharmaceuticals Inc|DAWN - Total Nilai Perusahaan

- indikator nilai buku ekuitas:

Nilai Buku saben Saham Day One Biopharmaceuticals|DAWN - Nilai Buku Bisnis|Rasio Kapitalisasi marang Aset Bersih dayonebio.com|DAWN - Aset Perusahaan

- data utang lan likuiditas:

Rasio Total Utang marang Ekuitas Day One|DAWN - Koefisien utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Day One|DAWN - Tanggungan utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Day One Biopharmaceuticals Inc|DAWN - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Day One Biopharmaceuticals|Likuiditas cepet dayonebio.com

- rincian asil keuangan lan kelipatan valuasi:

DAWN - Bathi pungkasan|Proyeksi bathi mangsa ngarep Day One|DAWN - Pangali P/E|Rega marang bathi mangsa ngarep Day One Bio|DAWN - Rasio kapitalisasi marang bathi lan wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Day One Biopharmaceuticals Inc|DAWN - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) Day One Biopharmaceuticals|DAWN - Bathi saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan dayonebio.com|DAWN - Wutah bathi ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Day One

- data pendapatan lan penerimaan dodolan:

DAWN - Total pendapatan perusahaan|Volume dodolan mangsa ngarep perusahaan Day One Biopharmaceuticals|DAWN - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang prakiraan pendapatan Day One Biopharmaceuticals Inc

Analisis umum perusahaan:Day One Biopharmaceuticals DAWN

Day One (DAWN) holds a monopoly position in the treatment of pediatric glioma, making revenue the key driver of value. This indicator compares current market capitalization with projected income, eliminating time gaps between quarterly reports. By analyzing changes in the forward P/S ratio, investors can see the immediate market reaction to news regarding Ojemda sales. This allows for an objective assessment of whether the market is overpaying for the uniqueness of this niche asset.

Pesaing wigati

Rasio rega marang prakiraan pendapatan Incyte INCY|Hutchison MediPharma - Rasio rega marang prakiraan pendapatan|NUVB - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Monopar Corp|INBX: Multiplikator Forward P/S|Prakiraan rega marang pendapatan I-Mab Biopharma IMAB|Multiplikator forward rega marang pendapatan FENC|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Heron Therapeutics Inc HRTX|Multiplikator forward rega marang pendapatan NVCT (Nuvectis)|CHRS (Coherus BioSciences, Inc) - Rega forward marang dodolan|Corbus Pharmaceuticals - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake CRDF (Cardiff Oncology Inc.)|BeyondSpring - Multiplikator Forward P/S|Rega forward marang dodolan BCAB (BioAtla, Inc.)|LIXT: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Citius Pharmaceuticals, Inc. (CTXR)|Rasio rega marang prakiraan pendapatan Cellectar Biosciences|BLRX: Rega forward marang dodolan|Multiplikator Forward P/S CANF|Multiplikator Forward P/S aprea.com (APRE)|Rasio rega marang prakiraan pendapatan Kazia Therapeutics Limited KZIA|SLXN (Silexion Therapeutics Corp.) - Rega mangsa ngarep marang pendapatan|NCNA: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep chimerix.com|CYCC: Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan GTHX|KRON (Kronos Bio Corp) - Multiplikator Forward P/S|Multiplikator Forward P/S Kintara Pharma|Multiplikator forward rega marang pendapatan ONCT (Oncternal Therapeutics)|PRTG - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep